MARKETS & INVESTING | Staff Reporter, Singapore

EDBI joins US$220m funding for China bio-pharma player

I-Mab will use the fund to further develop its pre-clinical and clinical assets.

EDBI backed the $300m (US$220m) Series C funding led by Hony Capital for I-Mab Biopharma that will be used to develop the firm's pre-clinical and clinical assets, an announcement revealed.

With China Renaissance as the sole financial advisor for the deal, other firms including Hillhouse Capital, HOPU Investments, CDH Investments, Ally Bridge Group C-Bridge Capital and Tasly Capital also joined the funding round.

“This round of financing will facilitate further development of our innovative assets in China and internationally”, I-Mab CEO and founder Dr. Jingwu Zang said.

Also readEDBI joins US$42m funding for US-based software

The firm received US$150m in a Series B funding in March 2017.

I-Mab’s focus is on discovery and development of First-in-Class and Best-in-Class biologics in the areas of immuno-oncology and immuno-inflammation. It is preparing to initiate clinical trials in China and the US.

Do you know more about this story? Contact us anonymously through this link.

Click here to learn about advertising, content sponsorship, events & rountables, custom media solutions, whitepaper writing, sales leads or eDM opportunities with us.

To get a media kit and information on advertising or sponsoring click here.